Key recent performance signals
PACS Group (PACS) has drawn investor attention after a mixed stretch in the stock, with a 1 day gain of about 1.5% and a roughly 5% move over the past week, in contrast with weaker returns over the past month and past 3 months.
See our latest analysis for PACS Group.
At a share price of $32.14, PACS Group’s recent 1 day and 7 day share price gains sit against weaker 1 month and year to date share price returns. The very large 1 year total shareholder return suggests earlier buyers have already seen substantial gains, which hints that recent momentum has cooled compared with the past year.
If you are comparing PACS Group with other healthcare names using recent price swings as a starting point, it can help to see what else is moving in specialist areas such as senior care and related services by scanning 37 healthcare AI stocks
With PACS Group trading at $32.14 against a consensus price target of $46.40 and only a small gap to some intrinsic estimates, you have to ask: is this a genuine value opening, or is the market already pricing in future growth?
Most Popular Narrative: 8.2% Undervalued
The most followed narrative pegs PACS Group’s fair value at $35, a touch above the last close at $32.14, and builds a detailed case around future earnings power and margin expansion.
Rising demand for post-acute and long-term care from an aging U.S. population, combined with PACS Group's expanding footprint of over 35,000 beds, creates room for continued top line growth as occupancy and patient volumes increase, supporting higher revenue and earnings.
Want to see what is baked into that $35 figure? The narrative leans on a multi year ramp in revenue, a step change in margins, and a reset in the earnings multiple. The key is how those moving parts line up across the forecast period, and what kind of profit profile they imply by the late 2020s.
Result: Fair Value of $35 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story can change quickly if the newer, lower occupancy facilities take longer to improve or if key state Medicaid reimbursement frameworks shift unfavorably.
Find out about the key risks to this PACS Group narrative.
Another way to look at PACS Group’s value
The story above leans on earnings forecasts and a fair value of $35. Yet the current P/E of 26.4x sits above both the US Healthcare industry at 22x and the peer average at 21.9x, and above a fair ratio of 22.9x. That premium could be upside, or just extra valuation risk for you to weigh.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on value and sentiment so far? Take a closer look at the numbers, assess both the potential upsides and the flagged concerns, and then weigh the 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If PACS Group has caught your eye, widen your watchlist now so you are not relying on a single story when fresh opportunities appear.
- Target potential mispricings by scanning 58 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
- Strengthen your search for stability by reviewing solid balance sheet and fundamentals stocks screener (40 results) that focus on companies with financial footing that can support their operations.
- Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before these ideas become widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com